Kaposi's sarcoma and human herpesvirus 8 infection do not protect HIV-1 infected homosexual men from AIDS dementia complex

被引:4
|
作者
Renwick, N
Weverling, GJ
Halaby, T
Portegies, P
Bakker, M
Schulz, TF
Goudsmit, J
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Limburg, Acad Hosp Maastricht, Dept Med Microbiol, Maastricht, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands
[5] Hannover Med Sch, Dept Virol, Hannover, Germany
关键词
AIDS dementia complex; epidemiology; HHV8; KSHV; Kaposi's sarcoma; risk;
D O I
10.1097/00002030-200111090-00012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To examine the association between Kaposi's sarcoma (KS), human herpes virus 8 (HHV8) and AIDS dementia complex (ADC). Design: A total of 599 HIV-1 infected homosexual men participated in a prospective cohort study (Amsterdam, 1984-1996). Methods: The risk for ADC in patients with prior KS or HHV8 infection was estimated using the Cox proportional hazards method with adjustments for antiretroviral medication and low CD4 cell counts. Results: Of the 599 participants, 290 (48.4%) had HHV8 antibodies, 99 (16.5%) had KS and 30 (5.0%) had ADC. ADC was diagnosed in 5.2% of participants with KS and 5.0% of those without KS, and in 4.8% of HHV8 seropositive compared to 5.2% seronegative individuals and thus was not associated with KS or HHV8 infection. Using a time-dependent Cox proportional hazards analysis with the date of KS as risk factor, the risk for ADC was 2.7 (95% confidence interval (CI), 0.92-7.96; P=0.07) and when only definite ADC was considered it was 3.5 (95% CI, 1.00-12.26; P=0.05). After adjusting for decreases in CD4 cell count and use of medication, the hazards ratio for participants with KS to develop ADC was 2.0 (95% CI, 0.66-5.77; P=0.23) and 2.6 (95% Cl, 0.73-9.12; P=0.14), respectively. HHV8 seropositivity, adjusted for the same variables, showed a risk for ADC of 0.85 (95% Cl, 0.41-1.77; P=0.66) and for definite ADC 0.69 (95% Cl, 0.27-1.73; P=0.42). The expected neuroprotective effects of antiretroviral medication were observed. Conclusions: KS or HHV8 does not significantly influence the risk for developing ADC in a group with a uniform risk for developing KS therefore we recommend caution in searching for a KS-associated or HHV8-derived therapy for ADC. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:2165 / 2169
页数:5
相关论文
共 50 条
  • [31] Detection of antibodies against viral capsid proteins of human herpesvirus 8 in AIDS-associated Kaposi’s sarcoma
    Stefanie André
    Octavian Schatz
    Johannes R. Bogner
    Heinz Zeichhardt
    Marina Stöffler-Meilicke
    Hans-Ulrich Jahn
    Reiner Ullrich
    Anne-Katharina Sonntag
    Roland Kehm
    J. Haas
    Journal of Molecular Medicine, 1997, 75 : 145 - 152
  • [32] Detection of antibodies against viral capsid proteins of human herpesvirus 8 in AIDS-associated Kaposi's sarcoma
    Andre, S
    Schatz, O
    Bogner, JR
    Zeichhardt, H
    StofflerMeilicke, M
    Jahn, HU
    Ullrich, R
    Sonntag, AK
    Kehm, R
    Haas, J
    JOURNAL OF MOLECULAR MEDICINE-JMM, 1997, 75 (02): : 145 - 152
  • [33] Cross-talk between human herpesvirus 8 and the transactivator protein in the pathogenesis of Kaposi's sarcoma in HIV-infected patients
    Chandra, A
    Demirhan, I
    Massambu, C
    Pyakurel, P
    Kaaya, E
    Enbom, M
    Urassa, W
    Linde, A
    Heiden, T
    Biberfeld, P
    Doerr, HW
    Cinatl, J
    Loewer, J
    Chandra, P
    ANTICANCER RESEARCH, 2003, 23 (1B) : 723 - 728
  • [34] Incidence of Kaposi's sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion
    Rezza, G
    Dorrucci, M
    Serraino, D
    Andreoni, M
    Giuliani, M
    Zerboni, R
    Sarmati, L
    Colangeli, V
    Salassa, B
    Monini, P
    Ensoli, B
    Pezzotti, P
    AIDS, 2000, 14 (11) : 1647 - 1653
  • [35] Expression and antigenicity of human herpesvirus 8 encoded ORF59 protein in AIDS-associated Kaposi's sarcoma
    Katano, H
    Sata, T
    Suda, T
    Nakamura, T
    Tachikawa, N
    Nishizumi, H
    Sakurada, S
    Hayashi, Y
    Koike, M
    Iwamoto, A
    Kurata, T
    Mori, S
    JOURNAL OF MEDICAL VIROLOGY, 1999, 59 (03) : 346 - 355
  • [36] Risk factors for Kaposi's sarcoma-associated herpesvirus infection among HIV-1-infected pregnant women in the USA
    Goedert, JJ
    Charurat, M
    Blattner, WA
    Hershow, RC
    Pitt, J
    Diaz, C
    Mofenson, LM
    Green, K
    Minkoff, H
    Paul, ME
    Thomas, DL
    Whitby, D
    AIDS, 2003, 17 (03) : 425 - 433
  • [37] Kaposi's sarcoma in Uganda: Risk factors for human herpesvirus 8 infection among blood donors
    Hladik, W
    Dollard, SC
    Downing, RG
    Kataaha, P
    Pellett, PE
    Karon, JM
    Mermin, J
    Lackritz, EM
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (02) : 206 - 210
  • [38] African ancestry and innate immunity contribute to the incidence of multicentric Castleman's disease in HIV-1/Kaposi's sarcoma herpesvirus-coinfected individuals
    Westrop, Samantha J.
    Lagos, Dimitrios
    Boshoff, Chris
    Bower, Mark
    Imami, Nesrina
    FUTURE VIROLOGY, 2012, 7 (07) : 729 - 734
  • [39] Seroreactivity to Kaposi's sarcoma-associated herpesvirus (Human herpesvirus 8) latent nuclear antigen in AIDS-associated Kaposi's sarcoma patients depends on CD4+ T-cell count
    Ueda Fick de Souza, Vanda Akico
    Pierrotti, Ligia Camera
    Sumita, Laura Masami
    Freire, Wilton Santos
    Cotrim Segurado, Aluisio Augusto
    Pannuti, Claudio Sergio
    JOURNAL OF MEDICAL VIROLOGY, 2007, 79 (10) : 1562 - 1568
  • [40] Infection with Kaposi's sarcoma-associated herpesvirus (KSHV) and human immunodeficiency virus (HIV) in relation to the risk and clinical presentation of Kaposi's sarcoma in Uganda
    Newton, R
    Ziegler, J
    Bourboulia, D
    Casabonne, D
    Beral, V
    Mbidde, E
    Carpenter, L
    Parkin, DM
    Wabinga, H
    Mbulaiteye, S
    Jaffe, H
    Weiss, R
    Boshoff, C
    BRITISH JOURNAL OF CANCER, 2003, 89 (03) : 502 - 504